Artificial intelligence and chimeric antigen receptor T-cell therapy
Lidia Gil, Maksymilian Grajek
Abstract
Therapy with the use of chimeric antigen receptor T-cell (CAR T-cells) is one of the most modern medical technologies in hemato-oncology, using, thanks to the advances in molecular biology, natural anti-cancer immune mechanisms. Nowadays, it is an extremely effective complement to conventional treatment and hematopoietic cell transplantation. Ongoing clinical trials show the enormous potential of this treatment beyond hemato-oncology. We discuss in this paper the potential use of Artificial intelligence (AI) in this setting. AI has been at the cutting edge of science in recent years. It has spread from computer science to areas like medicine, economics, finance and business. The use of and research into AI in medicine have become prominent due to its versatility and capabilities.